Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Ramatroban

Ramatroban

Ramatroban structure

Ramatroban 

structure
  • CAS No:

    116649-85-5

  • Formula:

    C21H21FN2O4S

  • Chemical Name:

    Ramatroban

  • Synonyms:

    9H-Carbazole-9-propanoic acid,3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-,(3R)-;9H-Carbazole-9-propanoic acid,3-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-,(R)-;(3R)-3-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid;BAY-u 3405;Ramatroban;Baynas;3-[(3R)-3-[(4-Fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid

  • Categories:

    Pharmaceutical Intermediates  >  Bulk Drug Intermediates

Description

WHite to Off-White SolidRamatroban, originally developed for the treatment of cardiovascular pathologies as thromboembolism, was finally introduced in Japan for the treatment of allergic rhinitis. It is a (3R)-enantiomer that can be synthesized in 5 steps from 3-oxo-1,2,3,4- tetrahydrocarbazole by stereoselective reductive amination, using S-phenethylamine as the chiral source, followed by hydrogenolysis, sulfonylation and finally 2-step Ncarboxyethylation. Ramatroban is a potent antagonis


Ramatroban is an organic molecular entity.|Ramatroban has been used in trials studying the treatment of Asthma.

Ramatroban Basic Attributes

416.467

416.47

P1ALI72U6C

DTXSID1046685

Characteristics

96.8

2.9

Crystalline solid.

1.43±0.1 g/cm3(Predicted)

134-135°

654.7±65.0 °C(Predicted)

349.7±34.3 °C

1.664

DMSO: ≥40mg/mL

4.94E-18mmHg at 25°C

Safety Information

NONH for all modes of transport

1

36/37/38

26-36/37/39-45

Xi

Stable at normal temperatures and pressures.

P261-P305 + P351 + P338

H315-H319-H335

|Warning|H302 (38.71%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 62 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid

Ramatroban Use and Manufacturing

A thromboxane receptor antagonist for use in the treatment of coronary artery disease.Potent dual antagonist of TP/DP 2 (CRTH2) prostanoid receptors (K i values are 4.3, 4.5 and > 10000 nM for hDP 2 , hTP and hDP 1 receptors respectively). Suppresses PGD 2 -induced migration of human eosinophils (IC 50 = 170 nM).

Computed Properties

Molecular Weight:416.5
XLogP3:2.9
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:6
Exact Mass:416.12060649
Monoisotopic Mass:416.12060649
Topological Polar Surface Area:96.8
Heavy Atom Count:29
Complexity:689
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Ramatroban

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.